Many countries report low initiation and continuation of PrEP. This doesn’t mean people don’t want the product. They might not want the program that’s offering it; or they might not be being reached. A “demand-creation cascade” such as the one proposed here for PrEP is one way to evaluate the program and the product. It would measure how many people received the full suite of demand-side activities the program hopes to deliver at a given stage. The precise set of steps would depend on the service-delivery design and strategy in question.
Towards a Demand Creation Cascade
Phases of Informed-Choice PrEP Counseling
This flow chart emerged from socio-behavioral research, including surveys and in-depth interviews with Kenyan and South African women. The research team set out with the goal of adapting the informed-choice approach used in family planning programs for use in PrEP, a prime example of fields learning from each other. The result is very clinic-centered; AVAC has added the column at the far right to reflect additional elements. However, it is a step towards much-needed exploration of how to make informed choice a reality in HIV prevention today.
Putting Women at the Center: Informed choice in 2018 and beyond
We need to give women the choice to use DTG or not and to use contraception if indicated and desired. We need to support choices across options, with risk reduction—not use of a specific product—as the primary outcome. We need to give women the choice to use DMPA-IM or –SC or not, and to use HIV prevention as desired.
AVAC Report 2018: No Prevention, No End!
AVAC’s 2018 annual state of the field report, No Prevention, No End! looks at today’s prevention crisis and offers context, analysis and strategy to turn that crisis around.
Oral PrEP Enrollment Snapshot
For trends in oral PrEP uptake, check out the Oral PrEP Enrollment Snapshot. This PowerPoint deck illustrates major findings from the tracker with heat maps showing where people are initiating PrEP, updates against targets and more. A PDF version is also available.
HIV Vaccine Science, Research, Updates and Advocacy
With HIV Vaccine Awareness Day (HVAD) in the spotlight earlier this month, AVAC’s May episode of PxPulse features four experts steeped in HIV vaccine research. Together they help set expectations for where the field is now and where it is going.
The Stories of HIV Vaccines in 2018—From science to stakeholder engagement
This four-pager explores stories about stakeholder engagement in the current suite of efficacy trials as well as stories around global support for vaccine research in the age of an expanded HIV prevention landscape.
Px Wire April-June 2018, Vol. 11, No. 2
In the new issue of Px Wire, AVAC gives our take on this year’s PEPFAR process for establishing the Country Operational Plans (COPs). These plans define what work will be done with PEPFAR money at the country level and how that work will be evaluated in each of the 63 countries that receive PEPFAR money.
From the Trenches, Advocates Share Their Prevention Priorities
In this episode of Px Pulse, our monthly podcast, we bring you two different conversations, each throwing a spotlight on different aspects of HIV prevention advocacy today. You’ll hear how the AVAC Partner Forum brought key issues into focus and how these advocates are sharpening their strategies. Then we turn to a global effort to accelerate prevention.
The Delivery Challenge
This figure shows the timeline to achieve public health targets related to a new intervention, both globally and (in dashed lines) in the US. The message: it takes time and, based on history, today’s prevention tools are on track. It appears in AVAC Report 2017: Mixed messages and how to untangle them.